Schistosomiasis Treatment Market Register a Hugh Growth In Healthcare Industry by 2026


Posted August 27, 2019 by psaraf

There are two forms of schistosomiasis, such as intestinal and urogenital.
 
Schistosomiasis is a disease caused by infection with freshwater parasitic worms. It can be acute or chronic infection mainly caused by parasitic worm’s blood flukes (trematode worms). There are two forms of schistosomiasis, such as intestinal and urogenital. According to the World Health Organization (WHO) reports in 2017, urogenital schistosomiasis is a high risk factor for the transmission of HIV infection in women.

People usually get infected during agriculture, domestic, and occupational activities, which exposes them to infected water resulting into immune reactions. Symptoms in intestinal schistosomiasis infected patient shows various symptoms such as, abdominal pain, diarrhea, liver and spleen enlargement, fibrosis of the bladder, and progressive damage of kidney. Other chronic symptoms includes blood in stool, blood in urea, genital lesions, nodules in seizures, paralysis, seminal vesicle, and vaginal bleeding. This symptoms could result into urogenital related schistosomiasis complications, such as bladder cancer, and long term irreversible consequences such as infertility.

According to the World Health Organization (WHO), around 218 million people required preventive treatments for schistosomiasis in 2015 and more than 66.5 million people were reported as treated for schistosomiasis in the same year. Further, WHO states that the transmission of schistosomiasis was reported in 78 countries. Schistosomiasis treatment is a major concern due to lack of proper medication and vaccination. Preventive chemotherapy for schistosomiasis includes praziquantel, metrifonate, and oxamniquine.

Request A Sample Copy: http://bit.ly/30D3zQS

Development of novel vaccines for the treatment of schistosomiasis is expected to propel the growth of schistosomiasis treatment market

According to the University of Nottingham in 2017, researchers have discovered the infiltrin protein on a parasitic egg, which may be responsible for this infectious disease. This discovery is expected create opportunities for targeted development of vaccination and treatments. Moreover, the College of Science at Oregon State University (OSU), discovered the new protein in Biomphalaria glabrata snail, known as Grctm6 in 2017. Research is in progresses use this protein as a biocontrol agent against schistosomiasis.

Dr. Afzal Siddiqui, a professor at the Tech Health Sciences Center, in 2015, received a patent for vaccine to treat schistosomiasis. The vaccine demonstrated successful results in pre-clinical trials and is undergoing clinical trials for safety and efficacy evaluation. Patent applications have also been filed in China, India, and Brazil. Dr. Siddiqui intends to develop and distribute this vaccine at affordable rates for the infected people. This is expected to stimulate growth in the schistosomiasis treatment market in future.

Increasing demand for preventive chemotherapy against schistosomiasis is expected to favor the growth of schistosomiasis treatment market

In May 2017, Global Schistosomiasis Alliance organized the world’s Neglected tropical diseases (NTDs) program hosted by World Health Organizations (WHO). Many organization from various economies supported this schistosomiasis control initiative program, which include Chinese Centers for Disease Control and Prevention (CDC), Research for Control and Elimination (SCORE), Swiss Tropical and Public Health Institute, The Federal Ministry of Health Ethiopia (FMHE), and The Ministry of Health (MoH).

The major players in schistosomiasis treatment market include, Chemos GmbH & Co. KG, Shin Poong Pharma.Co. Ltd., Meher Distributors Pvt. Ltd., Merck & Co., Salvensis, Bayer AG, LondonPharma Ltd, Merck & Co., Inc., 3S Corporation Kancera AB, aj Pharmaceuticals Ltd., Avanscure Lifesciences Pvt. Ltd, CBC Pharma., VHB Life Science Inc., Samarth Pharma Pvt. Ltd., Taj Pharmaceuticals Ltd.,and Egyptian International Pharmaceuticals Industries Co SAE (EIPICO). These companies offer various drugs, which are being used for preventive chemotherapy.

Click To Read More On: Schistosomiasis Treatment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:[email protected]
-- END ---
Contact Email [email protected]
Issued By Mr.Shah
Phone 2067016702
Business Address 1001 4th Ave,, #3200, WA,
1001 4th Ave,, #3200, WA,
Country India
Categories Health , Marketing , Medical
Tags schistosomiasis treatment market , schistosomiasis treatment market trends , schistosomiasis treatment market growth
Last Updated August 27, 2019